Madrigal PharmaceuticalsMIL:1MDGL 8 Days Payable is 185.33 as of Mar. 2026, which is 85% below its 10-year median of 1,199.09. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 705 Biotechnology companies, Madrigal Pharmaceuticals ranks better than 64.96% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1MDGL vs BMRN, AXSM, CYTK: Days Payable Comparison
For the Biotechnology subindustry, Madrigal Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Madrigal Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals (MIL:1MDGL) has a Days Payable of 185.33 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Madrigal Pharmaceuticals and its competitors. This is 85% below median its historical median of 1,199.09. Over the past decade, Madrigal Pharmaceuticals' Days Payable has ranged from 218.26 to 2,097.59. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #247 out of 705 companies in the Biotechnology industry, placing it in the top 35%.
Is Madrigal Pharmaceuticals' Days Payable too high?
Madrigal Pharmaceuticals' current Days Payable of 185.33 is 85% below median its 10-year median of 1,199.09. Over the past 10 years, this metric has ranged from a low of 218.26 to a high of 2,097.59. The Biotechnology industry median Days Payable is 113.36. Madrigal Pharmaceuticals' value of 185.33 is 63.5% above this industry median. Based on the distribution chart, Madrigal Pharmaceuticals ranks #247 out of 705 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Days Payable compare to BMRN and AXSM?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #247 out of 705 companies for Days Payable. This puts Madrigal Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 113.36. Madrigal Pharmaceuticals' value of 185.33 is 63.5% above this benchmark. Historically, Madrigal Pharmaceuticals' own Days Payable has ranged from 218.26 to 2,097.59 over the past decade. While the company's 10-year median is 1,199.09 vs. the industry median of 113.36, Madrigal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Madrigal Pharmaceuticals's current Days Payable of 185.33 is 63.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Madrigal Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Madrigal Pharmaceuticals's current Days Payable is 185.33, which is 85% below median its own 10-year median of 1,199.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Days Payable of 185.33. The current Days Payable is 185.33, which is 85% below median its 10-year median of 1,199.09 and 63.5% above the Biotechnology industry median of 113.36. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Days Payable is 185.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score
Get the complete analysis for MIL:1MDGL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1MDGL has been successfully added to your 
